Nurix Therapeutics Statistics
Total Valuation
NRIX has a market cap or net worth of $1.66 billion. The enterprise value is $1.12 billion.
Important Dates
The next estimated earnings date is Tuesday, April 7, 2026, after market close.
| Earnings Date | Apr 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRIX has 102.84 million shares outstanding. The number of shares has increased by 29.12% in one year.
| Current Share Class | 102.84M |
| Shares Outstanding | 102.84M |
| Shares Change (YoY) | +29.12% |
| Shares Change (QoQ) | +12.99% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 94.67% |
| Float | 86.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.73 |
| Forward PS | 24.59 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.02, with a Debt / Equity ratio of 0.10.
| Current Ratio | 7.02 |
| Quick Ratio | 6.87 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.63% and return on invested capital (ROIC) is -31.06%.
| Return on Equity (ROE) | -49.63% |
| Return on Assets (ROA) | -26.30% |
| Return on Invested Capital (ROIC) | -31.06% |
| Return on Capital Employed (ROCE) | -47.48% |
| Weighted Average Cost of Capital (WACC) | 14.58% |
| Revenue Per Employee | $264,921 |
| Profits Per Employee | -$834,249 |
| Employee Count | 317 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NRIX has paid $760,000 in taxes.
| Income Tax | 760,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.19% in the last 52 weeks. The beta is 1.97, so NRIX's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | -2.19% |
| 50-Day Moving Average | 17.72 |
| 200-Day Moving Average | 13.11 |
| Relative Strength Index (RSI) | 45.28 |
| Average Volume (20 Days) | 919,751 |
Short Selling Information
The latest short interest is 14.96 million, so 14.55% of the outstanding shares have been sold short.
| Short Interest | 14.96M |
| Short Previous Month | 15.20M |
| Short % of Shares Out | 14.55% |
| Short % of Float | 17.29% |
| Short Ratio (days to cover) | 11.39 |
Income Statement
In the last 12 months, NRIX had revenue of $83.98 million and -$264.46 million in losses. Loss per share was -$3.05.
| Revenue | 83.98M |
| Gross Profit | -232.92M |
| Operating Income | -285.67M |
| Pretax Income | -263.70M |
| Net Income | -264.46M |
| EBITDA | -277.53M |
| EBIT | -285.67M |
| Loss Per Share | -$3.05 |
Full Income StatementBalance Sheet
The company has $592.94 million in cash and $55.73 million in debt, with a net cash position of $537.21 million or $5.22 per share.
| Cash & Cash Equivalents | 592.94M |
| Total Debt | 55.73M |
| Net Cash | 537.21M |
| Net Cash Per Share | $5.22 |
| Equity (Book Value) | 538.75M |
| Book Value Per Share | 5.29 |
| Working Capital | 520.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$249.47 million and capital expenditures -$14.00 million, giving a free cash flow of -$263.47 million.
| Operating Cash Flow | -249.47M |
| Capital Expenditures | -14.00M |
| Free Cash Flow | -263.47M |
| FCF Per Share | -$2.56 |
Full Cash Flow StatementMargins
| Gross Margin | -277.36% |
| Operating Margin | -340.16% |
| Pretax Margin | -314.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.12% |
| Shareholder Yield | -29.12% |
| Earnings Yield | -15.96% |
| FCF Yield | -15.90% |
Analyst Forecast
The average price target for NRIX is $29.46, which is 82.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.46 |
| Price Target Difference | 82.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 43.02% |
| EPS Growth Forecast (5Y) | -40.67% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NRIX has an Altman Z-Score of 1.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.72 |
| Piotroski F-Score | 4 |
